Evolus Reaffirms 2025 Revenue Guidance of $295 Million to $305 Million

Reuters11-06

Evolus Reaffirms 2025 Revenue Guidance of $295 Million to $305 Million

Evolus Inc. has reaffirmed its 2025 net revenue guidance, projecting total net revenue between $295 million and $305 million for the year. The company also maintains its forecast for non-GAAP operating expenses in the range of $208 million to $213 million. In the third quarter of 2025, Evolus reported total net revenue of $69.0 million, representing a 13% increase compared to the same period in 2024 and a year-to-date growth of 10%. Notably, global Jeuveau® net revenue reached $63.2 million in Q3 2025, up from $59.7 million in Q2 2025, showing sequential growth that surpassed typical seasonal trends. Additionally, the launch of Evolysse™ generated $5.7 million in revenue, marking the strongest debut for a hyaluronic acid filler in over a decade. The company now expects to achieve positive non-GAAP operating income of $5 million to $7 million in the fourth quarter of 2025 and remains on track to achieve sustainable annual profitability beginning in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-049564), on November 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581702642?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 05:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581702642","market":"nz","top_or_hot":-1,"title":"Evolus Reaffirms 2025 Revenue Guidance of $295 Million to $305 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evolus Reaffirms 2025 Revenue Guidance of $295 Million to $305 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EOLS\">Evolus Inc.</a> has reaffirmed its 2025 net revenue guidance, projecting total net revenue between $295 million and $305 million for the year. The company also maintains its forecast for non-GAAP operating expenses in the range of $208 million to $213 million. In the third quarter of 2025, Evolus reported total net revenue of $69.0 million, representing a 13% increase compared to the same period in 2024 and a year-to-date growth of 10%. Notably, global Jeuveau® net revenue reached $63.2 million in Q3 2025, up from $59.7 million in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025, showing sequential growth that surpassed typical seasonal trends. Additionally, the launch of Evolysse™ generated $5.7 million in revenue, marking the strongest debut for a hyaluronic acid filler in over a decade. The company now expects to achieve positive non-GAAP operating income of $5 million to $7 million in the fourth quarter of 2025 and remains on track to achieve sustainable annual profitability beginning in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-049564), on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evolus Reaffirms 2025 Revenue Guidance of $295 Million to $305 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvolus Reaffirms 2025 Revenue Guidance of $295 Million to $305 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 05:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evolus Reaffirms 2025 Revenue Guidance of $295 Million to $305 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EOLS\">Evolus Inc.</a> has reaffirmed its 2025 net revenue guidance, projecting total net revenue between $295 million and $305 million for the year. The company also maintains its forecast for non-GAAP operating expenses in the range of $208 million to $213 million. In the third quarter of 2025, Evolus reported total net revenue of $69.0 million, representing a 13% increase compared to the same period in 2024 and a year-to-date growth of 10%. Notably, global Jeuveau® net revenue reached $63.2 million in Q3 2025, up from $59.7 million in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025, showing sequential growth that surpassed typical seasonal trends. Additionally, the launch of Evolysse™ generated $5.7 million in revenue, marking the strongest debut for a hyaluronic acid filler in over a decade. The company now expects to achieve positive non-GAAP operating income of $5 million to $7 million in the fourth quarter of 2025 and remains on track to achieve sustainable annual profitability beginning in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-049564), on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL6xQ9wD:1","article_id":"2581702642","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581702642","pubTimestamp":1762377805,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evolus Inc. has reaffirmed its 2025 net revenue guidance, projecting total net revenue between $295 million and $305 million for the year. The company also maintains its forecast for non-GAAP operating expenses in the range of $208 million to $213 million. In the third quarter of 2025, Evolus reported total net revenue of $69.0 million, representing a 13% increase compared to the same period in 2024 and a year-to-date growth of 10%. Notably, global Jeuveau net revenue reached $63.2 million in Q3 2025, up from $59.7 million in Q2 2025, showing sequential growth that surpassed typical seasonal trends. Additionally, the launch of Evolysse generated $5.7 million in revenue, marking the strongest debut for a hyaluronic acid filler in over a decade. The company now expects to achieve positive non-GAAP operating income of $5 million to $7 million in the fourth quarter of 2025 and remains on track to achieve sustainable annual profitability beginning in 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","EOLS":"Evolus Inc."},"translate_title":"Evolus重申2025年收入指引为2.95亿美元至3.05亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EOLS":0.9},"content_text":"Evolus Reaffirms 2025 Revenue Guidance of $295 Million to $305 Million\n    \n\nEvolus Inc. has reaffirmed its 2025 net revenue guidance, projecting total net revenue between $295 million and $305 million for the year. The company also maintains its forecast for non-GAAP operating expenses in the range of $208 million to $213 million. In the third quarter of 2025, Evolus reported total net revenue of $69.0 million, representing a 13% increase compared to the same period in 2024 and a year-to-date growth of 10%. Notably, global Jeuveau® net revenue reached $63.2 million in Q3 2025, up from $59.7 million in Q2 2025, showing sequential growth that surpassed typical seasonal trends. Additionally, the launch of Evolysse™ generated $5.7 million in revenue, marking the strongest debut for a hyaluronic acid filler in over a decade. The company now expects to achieve positive non-GAAP operating income of $5 million to $7 million in the fourth quarter of 2025 and remains on track to achieve sustainable annual profitability beginning in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-049564), on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581702642","isCrawlerRequest":true}